[Articles] Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial

Journal content Created on 28 Jul 2026 The Lancet Oncology

Published in

The Lancet Oncology, The Lancet (Reed Elsevier)

Content

There is no additional content. Please click on the source link to view more information.

Mark D Tyson, Jong-Kil Nam, Shreyas S Joshi, Edward M Uchio, Seung Il Jung, Trinity J Bivalacqua, Gary D Steinberg, Neal D Shore, James M Burke, Hiroshi Kitamura, Ben Tran, Roger Li

Attention!

On Life Science Network, we import abstract of articles published in the most popular journals. In addition, members of our network often upload full article pdfs of their research.

To access all content shared in our network and the source link, please sign up for an account. If you already have an account, sign in, or connect with LinkedIn, Google.

Stats

Recommendations n/a n/a positive of 0 vote(s)
Views 30
Comments 0

Comments

There are no comments yet.

Published in

Content

Attention!

Stats

Recommended by

Post a comment

Comments